BIOMARKER miRNA-146a SEBAGAI DETEKSI DINI YANG EFEKTIF UNTUK ALZHEIMER

Hidayatun Nisa, Rano Kurnia Sinuraya

Abstrak


Abstrak

Angka kejadian Alzheimer terus meningkat dari tahun ke tahun dan diproyeksikan meningkat hampir dua kali lipat setiap 20 tahun. Pemerintah Indonesia terus berusaha untuk menurunkan angka kejadian Alzheimer, salah satunya dengan melakukan pendeteksian. Akan tetapi pendeteksian alzheimer saat ini masih terbatas karena tingkat sensitivitas dan spesifisitas yang rendah. Untuk itu dicari metode pendeteksian yang terbaik di berbagai literature. Deteksi dini dapat dilakukan dengan pemeriksaan serum darah menggunakan penanda biologi (biomarker). Penelitian mengenai biomarker menunjukkan efektivitas dan efisiensi yang cukup baik dalam pendeteksian dini alzheimer. Biomarker yang dapat digunakan yaitu N-acetyl aspartate acid (NAA), Serum α1 – antikimotripsin (ACT), β-Amyloid, Tau-protein, dan miRNA-146a. Biomarker miRNA-146a dinilai memiliki potensi untuk digunakan karena memiliki sensitivitas 90% dan spesifisitas 100%.

Kata kunci: Alzheimer,  Deteksi Dini, Biomarker, miRNA-146a


Teks Lengkap:

PDF

Referensi


Abdallah CG, Coplan JD, Jackowski A, Sato JR, Mao X, Shungu DC, et al. 2013. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur Neuropsychopharmacol.23: 276-284.

Aguila JL, Koboldt DC, Black K, Chasse R, Norton J, Wilson RK, et al. 2015. Alzheimer's disease: rare variants with large effect sizes. Curr Opin Genet Dev. 33:49–55

Ahn, J. M. and Je, Y.C. 2013. Current Serum Lung Cancer Biomarkers. J Mol Biomark Diagn. Vol. 20(01): 1-7.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. 2011. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations for the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7:270–279.

Alexandrov, P. N. et al. 2013. microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol. 3, 365–373

Alzheimer’s Disease International. World Alzheimer Report 2009. Alzheimer’s Disease International. London.

Alzheimer’s Association. 2011 Alzheimer’s Association Report. 2011 Alzheimer’s diseases facts and figures. Alzheimers Dement. 7:208–244.

Andreasen, Niels., Lennart Minthon.,Pia Davidsson.,et al. 2010. Evaluation of CSF -tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice. American Medical Association. Vol 58, pp 373-379.

Anoop, Pradeep K, Singh, Reeba S. Jacob, et al. 2010. CSF Biomarkers for Alzheimer's Disease Diagnosis. Alzheimer. Vol 12(3). 606802. doi: 10.4061/2010/606802

Ariyannur PS, Madhavarao CN, Namboodiri AM. 2008. N-acetylaspartate synthesis in the brain: Mitochondria vs. microsomes. Brain Res. 1227: 34-41.

Banerjee S. 2010. Living well with dementia – development of the national dementia strategy for England. Int J Geriatr Psychiatry. 25:917–922.

Baranello, R.J., Bharani, K.L., Padmaraju, V., Chopra, N., Lahiri, D.K., Greig, N.H., et al. 2015. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer’s disease. Curr. Alzheimer Res. 12, 32–46.

Banerjee S. 2010. Living well with dementia – development of the national dementia strategy for England. Int J Geriatr Psychiatry.25:917–922.

Bittner D, Heinze HJ, Kaufmann J. 2013. Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in alzheimer’s disease: diverging behavior at three different brain regions. J Alzheimers Dis. 36: 155-163.

Borroni B. 2010. Blood cell markers in Alzheimer's disease: amyloid precursor protein form ratio in platelets. Exp. Gerontol. 45:53–56.

Brooker D, Fontaine JL, Evans S, Bray J, Saad K. 2014. Public health guidance to facilitate timely diagnosis of dementia: ALzheimer’s cooperative valuation in Europe recommendations. Int J Geriatr Psychiatry. 29:682–693.

Brookmeyera,R, Elizabeth Johnsona , Kathryn Ziegler-Grahamb , H. Michael Arrigh. 2007. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s & Dementia 3.186–191. doi:10.1016/j.jalz.2007.04.381

Britschgi M, et al. 2009. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc. Natl Acad. Sci. USA. 106:12145–12150.

Calderón L, Mora-Tiscareño A, Melo-Sánchez G, Rodríguez-Díaz J, TorresJardón R, Styner M, et al. 2015. A Critical Proton MR Spectroscopy Marker of Alzheimer’s Disease Early Neurodegenerative Change: Low Hippocampal NAA/ Cr Ratio Impacts APOE ε4 Mexico City Children and Their Parents. J Alzheimers Dis.48: 1065-75.

Clark PC, Kutner NG, Goldstein FC, Peterson-Hazen S, Garner V, Zhang R, et al. 2010. Impediments to timely diagnosis of Alzheimer’s disease in African Americans. J Am Geriatr Soc. 53(11):2012–7.

Cummings JL, Dubois B, Molineuvo JL, Scheltens P. 2013. International work group criteria for the diagnosis of Alzheimer disease. Med Clin North Am. 97:363–368.

de Leon MJ, Convit A, Wolf OT, Tarshish CY, De Santi S, Rusinek H, et al. 2010. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).Proc Natl Acad Sci U S A98, 10966-10971

De Lepeleire J, Wind AW, Iliffe S, Moniz-Cook ED, Wilcock J, Gonzalez VM, et al. 2008. nterdem Group The primary care diagnosis of dementia in Europe: An analysis using multidisciplinary, multinational expert groups. Aging Ment Health.12:568–576.

Denk, J. et al. 2011. MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer’s Disease. PLoS One. 10, e0126423, doi 0.1371/journal.pone.0126423

Duan, Y., Dong, S., Gu, F., Hu, Y. & Zhao, Z. 2012. Advances in the pathogenesis of Alzheimer’s disease: focusing on tau-mediated neurodegeneration. Transl Neurodegener. 1, 24, doi: 10.1186/2047-9158-1-24

Dubois, Anne M. Fagan, Piotr Lewczuk, Mony J. de Leon, and Harald Hampel. 2015. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimer. 11(1): 58–69.: DOI. 10.1016/j.jalz.2014.02.004

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. . 2007. Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 6:734–746.

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. 2010. Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol. 9:1118–1127.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. 2014. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol. 13:614–629.

Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. 2008. Imaging amyloid deposition in Lewy body diseases. Neurology. 71:903–10.

Hebert LE, Weuve J, Scherr PA, Evans DA. 2013. Alzheimer disease in the United States (2010–2050) estimated using the 2010 Census. Neurology. 80(19):1778–83.

Honea RA, Vidoni ED, Swerdlow RH, Burns JM. 2012. Alzheimer’s Disease Neuroimaging Initiative. Maternal family history is associated with Alzheimer’s disease biomarkers. J Alzheimers Dis.31(3):659–68.

Jiang, W. et al. 2013. Identification of active transcription factor and miRNA regulatory pathways in Alzheimer’s disease. Bioinformatics. 29, 2596–2602, doi: 10.1093/bioinformatics/btt423

Kamboh, et al. 2008. Alpha-1-antichymotrypsin (ACT or SERPINA3) Polymorphism May Affect Age-At-Onset and Disease Duration of Alzheimer’s Disease. Neurobiology of Aging. 27: 1435-1439.

Lieberman, et al. 2011. Serum α1-Antichymotrypsin Level as a Marker for Alzheimer-Type Dementia. Neurobiology of Aging. 16(5): 747-753.

Li, Y. & Kowdley, K. V. 2012. MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics.10, 246–253, doi: 10.1016/j. gpb.2012.07.005

Lukiw, W. J., Dua, P., Pogue, A. I., Eicken, C. & Hill, J. M. 2011. Upregulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler-Scheinker (GSS) syndrome. J Toxicol Environ Health A. 74, 1460–1468, doi: 10.1080/15287394.2011.618973

Maccioni, R.B, J. P. Muñoz, and L. Barbeito. 2010. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Archives of Medical Research. Vol. 32 (5), pp. 367–381.

Majer, A. et al. 2012. Early mechanisms of pathobiology are revealed by transcriptional temporal dynamics in hippocampal CA1 neurons of prion infected mice. PLoS Pathog. 8, e1003002, doi: 10.1371/journal.ppat.1003002

Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. 2006. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 63, 38-46.

Mayeux, R and Yaakov Stern. 2012. Epidemiology of Alzheimer Disease. Cold Spring Harb Perspect Med. 2:a006239

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. 2011. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute of Aging-Alzheimer Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7:263–269.

Moffett JR, Ariyannur P, Arun P, Namboodiri AM. 2014. Chapter 2.1-N -Acetylaspartate and N-Acetylaspartylglutamate in Central Nervous System Health and Disease. Magnetic Resonance Spectroscopy.71-90.

Moffett RJ, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. 2007. N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 81, 89-131.

Molinuevo JL and Rami L. 2013. Applying the IWG research criteria in clinical practice: Feasibility and ethical issues. Med Clin North Am. 97:477–484.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. 2010. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 67:122–31

Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, et al. 2014. Harmonized diagnostic criteria for Alzheimer’s disease: Recommendations. J Intern Med. 275:204–213.

Muller, M., Kuiperij, H. B., Claassen, J. A., Kusters, B. & Verbeek, M. 2014.M. MicroRNAs in Alzheimer’s disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging. 35, 152–158, doi: 10.1016/j.neurobiolaging.2013.07.005

Murray ME, Przybelski SA, Lesnick TG, Liesinger AM, Anthony S, Bing Z, et al. 2014. Early Alzheimer’s Disease Neuropathology Detected by Proton MR Spectroscopy. J Neurosci.34: 16247-16255.

Obulesu, M., Venu, R. & Somashekhar, R. 2011. Tau mediated neurodegeneration: an insight into Alzheimer’s disease pathology. Neurochem Res. 36, 1329–1335, doi: 10.1007/s11064-011-0475-5

Patel T, Blyth JC, Griffiths G, Kelly D, Talcott JB. 2014. Moderate relationships between NAA and cog- Assessment of plasma NAA Front Hum Neurosci. 9(12):23568-23575

Paslakis G, Träber F, Roberz J, Block W, Jessen F. 2014. N-acetyl-aspartate (NAA) as a correlate of pharmacological treatment in psychiatric disorders: A systematic review. Eur Neuropsychopharmacol.24: 1659-1675.

Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. 2007. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain. 130, 2837-2844.

Potter, Huntington, et al. 2010. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiology of Aging. 22 p: 923-930.

Qiu C, von Strauss E, Backman L, Winblad B, Fratiglioni L. 2013. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 80(20):1888–94

Revett TJ, Baker GB, Jhamandas J, Kar S. 2013 . Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci. 38(1):6-23. doi: 10.1503/jpn.110190

Saba, R., Sorensen, D. L. & Booth, S. A. 2014. MicroRNA-146a: A Dominant, Negative Regulator of the Innate Immune Response. Front Immunol. 5, 578, doi: 10.3389/fimmu.2014.00578

Scacchi, et al. 2010. Plasma α1-antichymotrypsin in Alzheimer’s Disease; Relantionship With APOE Genotypes. Neurobiology of Aging.22: 413-416.

Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. 2012. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 78(19):1456–63.

Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, et al. 2013 . zheimer’s Disease Neuroimaging Initiative. Predicting Cognitive Decline in Subjects at Risk for Alzheimer Disease by Using Combined Cerebrospinal Fluid, MR Imaging, and PET Biomarkers. Radiology. Feb;266(2):583-91. doi: 10.1148/radiol.12120010.

Sofie Solvten S, Ann-Britt Nygaard and Thomas Christeen. 2016. miRNA expression profiles in cerebrospinal fluid and bloodof patients with Alzheimer’s disease and other types of dementia-an exploratory study. Translational Neurodegenartion. 5:6. Doi 10.1186/s40035-016-0053-5

Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N . 2012 . "A meta-analysis of cytokines in Alzheimer disease". Biol Psychiat 68 (10): 930-941.

Strimbu, K and Jorge, A. T. 2010. What are Biomarkers? Curr Opin HIV AIDS. 5(6): 463-466.

Tang K. . 2009. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer‘s disease. J. Neurol. Sci. 240:53–58.

Tanna, S. 2015. A Public Health Approach to Innovation. WHO.

Wang, G. et al. 2016. MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer’s disease. Nature. Vol 6: 1-12

Weuve J, Hebert LE, Scherr PA, Evans DA. 2015. Prevalence of Alzheimer disease in U.S. states. Epidemiology. 26(1):e4-e6.

Wimo A, Jonsson L, Bond J, Prince M, Winblad B. 2010. Alzheimer Disease International The worldwide economic impact of dementia. Alzheimers Dement. 9:1–11.

Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, et al. 2013. The GERAS study: A prospective observational study of costs and resource use in community dwellers with Alzheimer’s disease in three European countries – study design and baseline findings. J Alzheimers Dis. 36:385–399.

Wootla B, Denic A, Watzlawik JO, Warrington AE, Rodriguez M. 2015. A single dose of a neuronbinding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis. J Neuroinflammation.12: 1-6.

World Health Organization. 2012. Dementia: a public health priority. Geneva: World Health Organization.

Yaffe K, Falvey C, Harris TB, Newman A, Satterfield S, Koster A, et al. 2013. Effect of socioeconomic disparities on incidence of dementia among biracial older adults: Prospective study. BMJ. 347:f7051.

Yamada K, et al. 2009. Aβ immunotherapy: intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. J. eurosci. 29:11393–11398




DOI: https://doi.org/10.24198/jf.v15i2.13227

DOI (PDF): https://doi.org/10.24198/jf.v15i2.13227.g6081

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved